1. Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI
- Author
-
Ming-Ran Xu, Rong-Fang Dai, Qing-Qi Wei, Jun Wang, Yue-Ying Feng, and Ying Hu
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Cognition ,Alzheimer Disease ,General Neuroscience ,Humans ,Cognitive Dysfunction ,Nerve Tissue Proteins ,Neuropsychological Tests ,Geriatrics and Gerontology - Abstract
The AD7c-NTP is a promising biomarker for AD diagnosis. However, the exact urinary AD7c-NTP concentration to differentiate AD from the mild cognitive impairment (MCI) remains inconclusive. We enrolled 98 and 90 clinical defined AD and MCI patients, respectively, and access their cognition impairment with Neuropsychiatric Inventory (NPI) and Mental State Examination (MMSE) along with their urinary AD7c-NTP. We demonstrated that urinary AD7c-NTP level in sequence from high to low was AD, MCI, and healthy groups ( P < .01), and the AD7c-NTP was positively and negatively correlated with the NPI and MMSE scores, respectively. Additionally, AD7c-NTP well-matched NPI subscale scores, including agitation, depression, and apathy ( P < .05). Importantly, the optimal cut-off AD7c-NTP level to distinguish the AD and MCI was .94 ng/mL (sensitivity 85.71% & specificity 73.91%). Conclusively, urinary AD7c-NTP could be used for cognition impairment evaluation and differentiated diagnosis of AD and MCI.
- Published
- 2022
- Full Text
- View/download PDF